On June 19, the three-day CPhI China 2023 kicked off grandly in Shanghai, where Apeloa Pharmaceutical attracted a multitude of booth visitors.

CPhI China, deeply rooted in the pharmaceutical industry for over two decades, is the preferred comprehensive platform for the pharmaceutical industry, which combines brand showcase, industry chain integration, and international trade. As one of important pharmaceutical manufacturers in the world, Apeloa has maintained excellent partnerships with large pharmaceutical companies and distributors worldwide, making it a focal point in many exhibition events.

At this exhibition, Apeloa’s grand and elegant booth design attracted numerous attendees, leading to engaging discussions. The company engaged in face-to-face discussions with new and existing customers, covering such topics as strategic planning in recent years, globalization process, R&D investment, platform build, technical capacity enhancement, and high-end capacity building. Apeloa's rapid and high-quality development has garnered full recognition from both new and existing customers, solidifying their determination to strengthen collaboration and providing ample momentum for comprehensive expansion of its business. Yuchuan Gong, Vice President and Head of Small Molecule CMC at BeiGene, expressed: "For the collaboration, what touches me deeply is Apeloa's sense of service. Apeloa has consistently gone above and beyond with the most enthusiastic and meticulous service for our projects. Both of us are committed to fostering cooperation with the utmost sincerity, promoting our partnership towards a broader future."

In the past three years, Apeloa has never ceased its pursuit of a brighter future. In recent five years, the company's business revenue has grown steadily, achieving a historic milestone of 10 billion yuan in 2022 for the first time. The company invested $1 billion to enhance its manufacturing and R&D capabilities. Nowadays, the company has eight manufacturing bases with chemical synthesis capacity exceeding 11,000m³ and fermentation capacity exceeding 6,000m³. It has also established its own analytical testing center and safety laboratory, which have passed CNAS certification and are in operation. The company has established three major technical platforms: Fluid Chemistry, Crystals & Powders, and Synthetic Biology & Enzymatic Catalysis, and is in the process of developing three additional technology platforms: Protac, ADC, and Peptides. In the next two years, the company will increase its R&D staff to more than 2,000.

The head of Apeloa said that the company has taken steady steps towards a global strategy. Its Boston and Frankfurt offices were put in use in 2022, and its subsidiary, Apeloa Pharmaceutical Co., Ltd. in Zhejiang, successfully passed the on-site inspection by U.S. FDA in early June this year. The company will continue to focus on technology-driven advanced manufacturing, providing customers with higher quality services, and establishing long-term strategic partnerships with customers for mutual prosperity.